Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 617-619

  Cervantes, A ^a   Glynne Jones, R ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; IRINOTECAN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM SURGERY; TOTAL MESORECTAL EXCISION; CANCER PROGNOSIS; CLINICAL EFFECTIVENESS; EDITORIAL; EVIDENCE BASED PRACTICE; PATIENT RISK; RECURRENCE RISK; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; ADENOCARCINOMA; DIAGNOSIS; EPIDEMIOLOGY; FEMALE; MALE; RECTAL NEOPLASMS; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS;

EID: 84926463361     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv021     Document Type: Editorial

References (19)

1. Breugom AJ, van Gijn W, Muller E et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomised phase III trial. Ann Oncol 2015; 26: 696-701.
2. Bosset JF, Calais G, Mineur L et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190.
3. Petersen SH, Harling H, Kirkeby LT et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3: CD004078.
4. Glynne-Jones R, Counsell N, Quirke P et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014; 25: 1356-1362.
5. Sainato A, Cernusco Luna Nunzia V, Valentini V et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 2014; 113: 223-229.
6. Hong YS, Nam BH, Kim KP et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-1253.
7. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant therapy for stage III colon cancer. N Eng J Med 2005; 352: 2696-2704.
8. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
9. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Eng J Med 2006; 355: 1114-1123.
10. Dewdney A, Cunningham D, Tabernero J et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-1627.
11. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organization for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386.
12. Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011; 305: 2335-2342.
13. Sloothaak DA, Geijsen DE, van Leersum NJ et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013; 100: 933-939.
14. de Campos-Lobato LF, Geisler DP, da Luz Moreira A et al. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011; 15: 444-450.
15. Fietkau R, Klautke G. Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer: the type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. J Clin Oncol 2008; 26: 507-508.
16. Collette L, Bossett JF. Letter in reply to Fietkau R and Klautke G. J Clin Oncol 2008; 26: 508-509.
17. Roedel C, Liersch T, Fietkau R et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5- fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ ARO/AIO-04 randomized phase III trial. Proc Am Soc Clin Oncol 2014; 32(suppl):abstr 3500.
18. Breugom AJ, Swets M, Bosset JF et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 200-207.
19. Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6):vi81-vi88.